NovoCure, Ltd. announced the appointment of Louis J. Lavigne Jr., James T. Lenehan, Robert J. Mylod Jr. and Charles G. Phillips III to its board of directors. The new members are independent directors and provide Novocure extensive financial and healthcare industry expertise. Novocure is a private, commercial stage oncology company dedicated to the development and commercialization of NovoTTF(TM) Therapy, its novel and proprietary treatment for solid cancer tumors.

Louis J. Lavigne Jr. is currently Managing Director of Lavrite, LLC, a management consulting firm specializing in the areas of corporate finance, accounting, growth strategy and management. James T. Lenehan served in a variety of positions at Johnson & Johnson from October 1976 until he retired as President and Vice Chairman in June 2004. During his 28-year tenure with Johnson & Johnson, Mr. Lenehan held executive positions including President of McNeil Consumer Products Company, Worldwide Chairman, Medical Devices and Diagnostics Group and Worldwide Chairman, Consumer Pharmaceuticals & Professional Group.

He is a member of the board of directors of Medtronic Inc. Robert J. Mylod Jr. served as Vice Chairman and Head of Worldwide Strategy and Planning at priceline.com from January 2009 to March 2011. Charles G. Phillips III served as Chief Operating Officer of Prentice Capital Management, LLC, an investment management firm, from 2005 until his retirement in 2008. Mr. Phillips was previously a managing director from 1991 to 2002 and President from 1998 to 2001 of Gleacher & Co., and its successor, Gleacher NatWest, an investment bank specializing in mergers and acquisition and direct private investment.